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Abstract
The natural compound pancratistatin (PST) is a non-genotoxic inducer of apoptosis in a variety of cancers. It exhibits cancer
selectivity as non-cancerous cells are markedly less sensitive to PST. Nonetheless, PST is not readily synthesized and is
present in very low quantities in its natural source to be applied clinically. We have previously synthesized and evaluated
several synthetic analogues of 7-deoxypancratistatin, and found that JC-TH-acetate-4 (JCTH-4), a C-1 acetoxymethyl
analogue, possessed similar apoptosis inducing activity compared to PST. In this study, notoriously chemoresistant
osteosarcoma (OS) cells (Saos-2, U-2 OS) were substantially susceptible to JCTH-4-induced apoptosis through mitochondrial
targeting; JCTH-4 induced collapse of mitochondrial membrane potential (MMP), increased reactive oxygen species (ROS)
production in isolated mitochondria, and caused release of apoptosis inducing factor (AIF) and endonuclease G (EndoG)
from isolated mitochondria. Furthermore, JCTH-4 selectively induced autophagy in OS cells. Additionally, we investigated
the combinatory effect of JCTH-4 with the natural compound curcumin (CC), a compound found in turmeric spice,
previously shown to possess antiproliferative properties. CC alone had no observable effect on Saos-2 and U-2 OS cells.
However, when present with JCTH-4, CC was able to enhance the cytotoxicity of JCTH-4 selectively in OS cells. Such
cytotoxicity by JCTH-4 alone and in combination with CC was not observed in normal human osteoblasts (HOb) and normal
human fetal fibroblasts (NFF). Therefore, this report illustrates a new window in combination therapy, utilizing a novel
synthetic analogue of PST with the natural compound CC, for the treatment of OS.
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Introduction
For many centuries, a plethora of natural products have been
used in traditional medicine for the treatment of numerous
ailments. One such product includes the Curcuma longa herb [1].
Traditionally, this herb has been used to treat anorexia,
rheumatism, sinusitis, hepatic disorders, and inflammation [2].
More recently, a component of this herb, the compound curcumin
(CC) also referred to as (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphe-
nyl)-1,6-heptadiene-3,5-dione or diferuloylmethane, has been
recognized for its antiproliferative properties in treating cancer
[1]. In particular, CC has been shown to regulate expression of
genes implicated in cell proliferation, metastasis, chemotherapy
resistance, and angiogenesis [1,3]. The anti-neoplastic properties
of CC are exhibited in many types of malignancies including
breast cancer, colon cancer, kidney cancer, leukemia, prostate
cancer, melanoma, and osteosarcoma (OS) [1,4].
OS, a primary malignant bone tumor, is an extremely
aggressive form of cancer associated with poor prognosis [5]. It
occurs most commonly in the developing bones of children and
adolescents and is often accompanied by lung metastases and
subsequent respiratory failure [6,7]. Current treatment strategies
include surgery and radiation therapy with adjuvant chemother-
apy with agents such as doxorubicin, cisplatin, methotrexate,
etoposide, and ifosfamide at high doses [6]. Despite the use of
these chemotherapeutics, the 5-year survival rate for patients with
metastatic OS is only 20% [6]. Furthermore, toxicity has been
associated with the use of these drugs and chemoresistance
frequently develops in this aggressive cancer; thus, more selective
and effective chemotherapeutics are needed for OS [7–11].
Previously, we have shown the natural compound pancratistatin
(PST), isolated from the Hymenocallis littoralis plant, to induce
cytotoxicity in a number of malignant cell lines at concentrations
below 1 mM and reduce the volume of human prostate and colon
tumor xenografts [12–18]. Contrasting from many approved
chemotherapeutics in use, non-cancerous cell lines are markedly
less sensitive to PST [12–18]. PST however, is present in only
parts per million quantities in its natural source and there have
been many difficulties associated with its chemical synthesis;
therefore, the major bottleneck of this compound has been its low
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synthesized and screened 7-deoxypancratistatin derivatives and
have identified a C-1 acetoxymethyl analogue, JC-TH-acetate-4
(JCTH-4), with comparable efficacy and specificity to PST against
several cancer cell lines [19].
Evasion of apoptosis, or type I programmed cell death, as a
result of abnormalities in pathways leading to apoptosis plays a
major role in the development of cancer; therefore, much effort
has been made to manipulate and restore apoptosis as a way to
treat cancer [20,21]. Apoptosis can be activated in response to a
death ligand binding to its corresponding death receptor or in
response an internal stress stimulus such as DNA damage [22]. In
response to such internal stress, various proapoptotic proteins are
upregulated and translocated to the mitochondria where they
induce mitochondrial membrane permeabilization, collapse of
mitochondrial membrane potential (MMP), and release of
apoptogenic factors which subsequently execute apoptosis directly
or indirectly [23]. Execution of this pathway yields nuclear and
cellular condensation, membrane blebbing, and formation of
apoptotic bodies which are phagocytosed by phagocytes or
neighbouring cells [24]. As well as apoptosis, much focus has
been put on the implications of other cell death pathways in cancer
therapy [25,26].
Autophagy has been recognized as a cellular pro-survival
response to various forms of sublethal cellular stress such as DNA
damage, deficiencies in growth factors and nutrients, protein
aggregates, reactive oxygen species, hypoxia, pathogens, and
defective organelles [25]. Once this pathway is activated,
cytoplasmic material is sequestered by double-membraned vesicles
known as autophagosomes. These autophagosomes fuse with
lysosomes to form autolysosomes which degrade the contained
cytoplasmic contents [26]. Extensive activation of autophagy
however, can result in a pro-death response leading to autophagic
cell death, classified as type II programmed cell death [27].
In this report, we demonstrate JCTH-4 to be a potent inducer
of apoptosis and autophagy in OS cells (Saos-2, U-2 OS) via
mitochondrial targeting. Furthermore, CC was able to potentiate
the cytotoxic effects of JCTH-4 in Saos-2 and U-2 OS cells. The
normal human fetal fibroblast (NFF) and normal human osteoblast
(HOb) cell lines utilized in this study were drastically less sensitive
to JCTH-4 alone and in combination with CC, presenting a
potential therapeutic window for this aggressive malignancy.
Materials and Methods
Cell Culture
An OS cell line, Saos-2 (American Type Culture Collection,
Cat. No. HTB-85, Manassas, VA, USA), was grown in McCoy’s
5A Medium Modified (Sigma-Aldrich Canada, Mississauga, ON,
Canada) supplemented with 15% (v/v) fetal bovine serum (FBS)
standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/
mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada).
An additional OS cell line, U-2 OS (American Type Culture
Collection, Cat. No. HTB-96, Manassas, VA, USA), was grown in
McCoy’s 5A Medium Modified (Sigma-Aldrich Canada, Mis-
sissauga, ON, Canada) supplemented with 10% (v/v) FBS
standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/
mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada).
Apparently NFF cells (Coriell Institute for Medical Research, Cat.
No. AG04431B, Camden, NJ, USA) were cultured in Dulbecco’s
Modified Eagle’s Medium, High Glucose (Thermo Scientific,
Waltham, MA, USA) supplemented with 15% (v/v) FBS standard
(Thermo Scientific, Waltham, MA, USA) and 10 mg/mL
gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada).
HOb cells (Cell Applications, Inc., Cat. No. 406-05a, San Diego,
CA, USA) were cultured in Osteoblast Growth Medium (Cell
Applications, Inc., Cat. No. 417-500, San Diego, CA, USA). All
cells were grown at 37uC and 5% CO2.
Cell Treatment
After culturing cells to 60–70% confluence, they were treated
with CC (Sigma-Aldrich Canada, Cat. No. C7727, Mississauga,
ON, Canada), tamoxifen (TAM) citrate salt (Sigma-Aldrich, Cat.
No. T9262, Mississauga, ON, Canada), the broad spectrum
caspase inhibitor Z-VAD-FMK (EMD Chemicals, Gibbstown,
NJ, USA), and JCTH-4 (((1S, 2S, 3R, 4S, 4aR, 11bR)-2, 3, 4-
Trihydroxy-6-oxo-1, 2, 3, 4, 4a, 5, 6, 11b-octahydro-[1,3]diox-
olo[4,5-j]phenanthridin-1-yl)methyl Acetate) at the indicated doses
and durations. As per a previously published protocol, JCTH-4
was produced by chemoenzymatic synthesis from bromobenzene
[19]. All stock solutions of drugs were made with dimethylsulfoxide
(Me2SO).
Nuclear Staining
Post treatment and incubation with the aforementioned drugs,
Hoechst 33342 dye (Molecular Probes, Eugene, OR, USA) was
used to stain the nuclei. Cells were incubated with 10 mM Hoechst
33342 dye for 5 minutes and images were taken at 4006
magnification on a Leica DM IRB inverted fluorescence
microscope (Wetzlar, Germany).
Annexin V Binding Assay
The Annexin V binding assay was performed to verify the
induction of apoptosis. Following drug treatment, cells were
washed two times using phosphate buffer saline (PBS), resus-
pended in Annexin V binding buffer (10 mM HEPES, 10 mM
NaOH, 140 mM NaCl, 1 mM CaCl2, pH 7.6), and incubated
with Annexin V AlexaFluor-488 (1:50) (Sigma-Aldrich Canada,
Mississauga, ON, Canada) for 15 minutes. Micrographs were
taken at 4006 magnification on a Leica DM IRB inverted
fluorescence microscope (Wetzlar, Germany).
WST-1 Assay for Cell Viability
The WST-1 based colorimetric assay was performed according
to the manufacturer’s protocol (Roche Applied Science, India-
napolis, IN, USA) to quantify cell viability as a function of active
cell metabolism. 96-well clear bottom tissue culture plates were
seeded with approximately 6.0610
3 Saos-2 cells/well, 7.5610
3
U-2 OS cells/well, 5.0610
3 NFF cells/well, or 4.0610
3 HOb
cells/well and treated with JCTH-4 and CC at the indicated
concentrations and for the indicated durations. Following
treatment, the WST-1 reagent, which is processed to formazan
by cellular enzymes, was added to each well and incubated for
4 hours at 37uC. Absorbance readings were taken at 450 nm on a
Wallac Victor
3TM 1420 Multilabel Counter (PerkinElmer,
Woodbridge, ON, Canada) to quantify the formazan product
and were expressed as percentages of the solvent control groups
(Me2SO).
Tetramethylrhodamine Methyl Ester (TMRM) Staining
TMRM (Gibco BRL, VWR, Mississauga, ON, Canada) was
used as an indicator for MMP. Cells were grown on coverslips and
treated with the indicated concentrations of JCTH-4 and CC for
the indicated durations. Subsequent to drug treatment, cells were
incubated with 200 nM TMRM for 45 minutes at 37uC.
Micrographs were taken at 4006 magnification on a Leica DM
IRB inverted fluorescence microscope (Wetzlar, Germany).
PST Analogue & Curcumin for Osteosarcoma Therapy
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Mitochondria were isolated from untreated Saos-2 and U-2 OS
cells. These cells were washed two times with cold PBS, resuspended in
h y p o t o n i cb u f f e r( 1m ME D T A ,5m MT r i s – H C l ,2 1 0m Mm a n n i t o l ,
70 mMsucrose, 10 mML e u - p e p ,1 0mMPep-A,and 100 mMPM S F ) ,
manually homogenized, and subsequently centrifuged at 6006gf o r
5m i n u t e sa t4 uC. The supernatant was centrifuged at 15,0006gf o r
15 minutes at 4uC. The resulting cytosolic supernatant was discarded
and the mitochondrial pellet was resuspended in cold reaction buffer
(2.5 mM malate, 10 mM succinate, 10 mM Leu-pep, 10 mMP e p - A ,
and 100 mMP M S Fi nP B S ) .
Amplex Red Assay
Generation of reactive oxygen species (ROS) was quantified
with Amplex Red (Molecular Probes, Eugene, OR, USA). Opaque
96-well plates were equally loaded with isolated mitochondria
suspended in cold reaction buffer, with 20 mg of protein/well. The
Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA USA)
was used for protein quantification as per manufacturer’s protocol.
Isolated mitochondria were incubated with the indicated concen-
trations of drugs, Amplex Red reagent at a final concentration of
50 mM, and horseradish peroxidase (Sigma-Aldrich Canada,
Mississauga, ON, Canada) in the ratio of 6 U/200 mL. Paraquat
(PQ) (Sigma-Aldrich Canada, Mississauga, ON, Canada) was used
as a positive control at 250 mM. Fluorescence readings were
acquired after 2 hours of incubation at Ex. 560 nm and Em.
590 nm on a spectrofluorometer (SpectraMax Gemini XS,
Molecular Devices, Sunnyvale, CA, USA). Fluorescence readings
were expressed as relative fluorescence units (RFU).
Treatment of Isolated Mitochondria & Evaluation of
Apoptogenic Factor Release
Mitochondria isolated from Saos-2 and U-2 OS cells were
directly treated with JCTH-4 and CC at the indicated concentra-
tions for 2 hours in cold reaction buffer (2.5 mM malate, 10 mM
succinate, 10 mM Leu-pep, 10 mM Pep-A, and 100 mM PMSF in
PBS). The control group was treated with solvent (Me2SO). After
treatment, mitochondrial samples were vortexed and centrifuged at
15,0006g for 15 minutes at 4uC. The resultant supernatant and
mitochondrial pellet (resuspended in cold reaction buffer) samples
were subjected to western blot analyses to monitor for mitochon-
drial release or retention of apoptogenic factors.
Cellular Lysate Preparation
Cells were treated for 72 hours with the indicated concentra-
tions of JCTH-4, CC, and TAM, and subsequently homogenized
manually in cold hypotonic buffer (10 mM Tris HCl at pH 7.2,
5 mM KCl, 1 mM MgCl2, 1 mM EGTA, 1% Triton-X-100;
10 mM Leu-pep, 10 mM Pep-A, and 100 mM PMSF). Cell lysates
were stored at -20uC until use.
Western Blot Analyses
SDS-PAGE was performed on the protein samples. Electropho-
resed proteins were transferred to a nitrocellulose membrane. For
1 hour, membranes were blocked with a 5% w/v milk TBST (Tris-
Buffered Saline with Tween-20) solution. The membranes were
probed with various primary antibodies overnight at 4uCf o r
microtubule-associated protein1 light chain 3 (LC3) raised in rabbit
(1:500) (Novus Biologicals, Cat. No. NB100-2220, Littleton, CO,
USA), b-Actin raised in mouse (1:1000) (Santa Cruz Biotechnology,
Inc., Cat. No. sc-81178, Paso Robles, CA, USA), apoptosis inducing
factor (AIF) raised in rabbit (1:1000) (Abcam, Cat. No. ab1998,
Cambridge, MA, USA), endonuclease G (EndoG) raised in rabbit
(1:1000) (Abcam, Cat. No. ab9647, Cambridge, MA, USA), and
succinate dehydrogenasesubunitA(SDHA)raisedinmouse(1:1000)
(Santa Cruz Biotechnology, Cat. No. sc-59687, Paso Robles, CA,
USA). Following primary antibody incubation, membranes were
washed once for 15 minutes andtwice for5 minutes with TBST and
were incubated with an anti-mouse (1:2000) or an anti-rabbit
(1:2000) horseradish peroxidase-conjugated secondary antibody
(Abcam, Cat. No. ab6728 & ab6802, Cambridge, MA, USA) for
1h o u r a t 2 5 uC. After secondary antibody incubation, the
membranes were washed three times for 5 minutes in TBST. Bands
were visualized with enhanced chemiluminescence reagent (Sigma-
Aldrich Canada, Cat. No. CPS160, Mississauga, ON, Canada) and
densitometry analyses were performed using ImageJ software.
Monodansylcadaverine (MDC) Staining
MDC (Sigma-Aldrich Canada, Mississauga, ON, Canada) was
used to detect autophagic vacuoles. Cells were grown on coverslips
and treated with TAM, JCTH-4, and CC at the indicated
concentrations and for the indicated durations. After treatment,
cells were incubated with 0.1 mM MDC for 15 minutes. Using a
Leica DM IRB inverted fluorescence microscope (Wetzlar,
Germany), micrographs were taken at 4006magnification.
Figure 1. Comparison of chemical structures. Structures of (A) Pancratistatin (PST) and (B) JC-TH-acetate-4 (JCTH-4).
doi:10.1371/journal.pone.0028780.g001
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PI (Sigma-Aldrich Canada, Mississauga, ON, Canada) was used
to detect cell lysis. Cells were incubated with 1 mg/mL PI for
10 minutes and images were taken at 4006 magnification on a
Leica DM IRB inverted fluorescence microscope (Wetzlar,
Germany).
Results
JCTH-4 causes selective cytotoxicity in OS cells in a time
and dose-dependent manner
As we have previously found PST (Figure 1A) to be effective
in producing cytotoxicity selectively in various cancer cell lines,
we evaluated the activity of JCTH-4 (Figure 1B) in the OS cell
lines Saos-2 and U-2 OS using the WST-1 based colorimetric
assay for cell viability. JCTH-4 decreased cell viability in a time
and dose dependent manner and had a half-maximal inhibitory
concentration (IC50) value of 0.25 mMa f t e r4 8h o u r si nb o t h
Saos-2 and U-2 OS cells (Figure 2A,B). Importantly, JCTH-4
was selective to OS cells as HOb and NFF cells were drastically
less sensitive to this compound (Figure 2C). Although HOb cells
are the non-cancerous counterpart to the OS cell lines used in
this study, we also evaluated the toxicity of this compound on
another non-transformed non-cancerous human fetal fibroblast
cell line (NFF) to confirm the selective anti-cancer activity of this
compound.
Figure 2. JCTH-4 causes selective cytotoxicity in OS cells in a time and dose-dependent manner. Effect of JCTH-4 on cellular viability of
OS cells was determined by the WST-1 based colorimetric assay. (A) Saos-2 and (B) U-2 OS cells were treated with JCTH-4 and the WST-1 reagent was
used to quantify cell viability. Absorbance was read at 450 nm and expressed as a percent of the control (Me2SO). Values are expressed as mean 6 SD
from quadruplicates of 3 independent experiments. *p,0.05, **p,0.01, ***p,0.001 versus solvent control (Me2SO). (C) Effect on cellular viability of
HOb and NFF cells treated with JCTH-4 compared to Saos-2 and U-2 OS cells after 72 hours. The WST-1 reagent was used to quantify cellular viability.
Absorbance was read at 450 nm and expressed as a percent of the solvent control (Me2SO). Values are expressed as mean 6 SD from quadruplicates
of 3 independent experiments. *p,0.005 versus Saos-2 cells; #p,0.005 versus U-2 OS cells.
doi:10.1371/journal.pone.0028780.g002
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OS cells
The natural compound CC has been shown to possess anti-
cancer properties as well as the ability to enhance the efficacy of
various chemotherapeutics [28,29]. Thus, we evaluated the
combinatorial effects of CC and JCTH-4 in OS cells. CC alone
at 5 mM had no significant effect on Saos-2 (96 hours) and U-2 OS
cells (72 hours); however, when used in combination, CC was able
to selectively potentiate the effect of JCTH-4 in these OS cell lines
as HOb and NFF cells were markedly less sensitive to this
combinatorial insult (Figure 3A–D).
JCTH-4 alone and in combination with CC induces
apoptosis selectively in OS cells
Nuclear and cellular morphology was monitored in Saos-2 and
U-2 OS cells treated with JCTH-4 and CC at the indicated
Figure 3. CC potentiates the cytotoxicity of JCTH-4 selectively in OS cells. EffectofJCTH-4&CCin combinationoncellularviability ofOScells
was determined by the WST-1 based colorimetric assay. (A) Saos-2 (96 hours), (B) U-2 OS (72 hours), (C) HOb (72 hours), and (D) NFF (72 hours) cells
were treated with JCTH-4 and CC and the WST-1 reagent was used to quantify cellular viability. Absorbance was read at 450 nm and expressed as a
percent of the solvent control (Me2SO). Values are expressed as mean 6 SD from quadruplicates of 3 independent experiments. *p,0.05, **p,0.01,
versus solvent control (Me2SO); {p,0.001 versus 0.25 mM JCTH-4; {{p,0.01 versus 0.5 mM JCTH-4; #p,0.001 versus 5 mMC C ;@ p,0.001 versus
0.25 mM JCTH-4+5 mM CC treatment with Saos-2 cells (Figure 3A); &p,0.01 versus 0.5 mM JCTH-4+5 mM CC treatment with U-2 OS cells (Figure 3B).
doi:10.1371/journal.pone.0028780.g003
Figure 4. JCTH-4 alone and in combination with CC yields apoptotic morphology in OS cells. Nuclearandcellularmorphologyof (A) Saos-
2 cells after 96 hours of treatment and(B) U-2 OS cells after 72 hours of treatment. Cells were treated with JCTH-4, CC, andsolvent control (Me2SO). Post
treatment, the cells were stained with Hoechst 33342 dye. Corresponding phase micrographs are shown below the Hoechst micrographs. Apoptotic
morphology is evident in cells with bright and condensed nuclei accompanied by apoptotic bodies, as well as cell shrinkage and blebbing. Images were
taken at 4006magnification on a fluorescent microscope. Scale bar=15 mm. All images are representative of 3 independent experiments.
doi:10.1371/journal.pone.0028780.g004
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Hoechst staining, JCTH-4 produced brightly stained, condensed
nuclei, and apoptotic bodies while corresponding phase micro-
graphs revealed cell condensation and blebbing in a dose
dependent manner; such features are indicative of apoptosis
(Figure 4A,B). This morphology was not present in OS cells
treated with 5 mM CC alone (Figure 4A,B); however, the
frequency of these morphological changes induced by JCTH-4
was enhanced when used with 5 mM CC (Figure 4A,B). All of the
aforementioned treatments did not produce apoptotic morphology
in both HOb and NFF cells (Figure 5A,B). Selective induction of
apoptosis by JCTH-4 alone and in combination with CC in OS
cells was confirmed by Annexin V binding to externalized
phosphatidylserine, a marker for apoptosis, indicated by green
fluorescence (Figure 6–7) [30].
JCTH-4 alone and in combination with CC targets OS cell
mitochondria
In preceding studies, PST has been found to exert its effects by
way of mitochondrial targeting; thus, mechanistic studies were
performed to verify such targeting by JCTH-4 in OS cells [13–
15,16,17]. Saos-2 and U-2 cells were treated for 96 and 72 hours
respectively with JCTH-4 and CC at the indicated concentrations
and stained with Hoechst dye and TMRM, an indicator of intact
MMP and impermeabilized mitochondrial membrane, depicted
by red fluorescence. Greatest dissipation of MMP was seen in OS
cells treated with 1 mM JCTH-4 (Figure 8A,B). Dissipation of
MMP was also seen with lower doses of JCTH-4; this dissipation
by JCTH-4 was enhanced with the addition of 5 mM CC, which
had no observable effect on MMP its own (Figure 8A,B).
Additionally, none of these treatments yielded MMP dissipation
in HOb and NFF cells (Figure 9A,B).
Oxidative stress produced in the mitochondria has been
associated the dysfunction of this organelle; in particular,
mitochondrial permeabilization and apoptogenic factor release
have both been linked to increases in ROS production [31–34].
After apoptogenic factors are released into the cytosol from the
mitochondria, some can execute apoptosis by translocating to the
nucleus or participating in cytosolic downstream pathways [23].
To evaluate the ability of JCTH-4 to induce the generation of
ROS directly in mitochondria of OS cells, mitochondria were
isolated from Saos-2 and U-2 OS cells, treated directly with
various doses of JCTH-4 and CC for 2 hours, and analyzed for
ROS production with Amplex Red. JCTH-4 alone at several
concentrations caused an increase in ROS production in OS cells
which was further enhanced by the addition of 5 mMC C
(Figure 10A,B). 5 mM CC alone also increased ROS generation
in isolated OS cell mitochondria (Figure 10A,B) PQ, known to
cause ROS production in mitochondria, was used as a positive
control [34]. Furthermore, isolated mitochondria of OS cells
treated with JCTH-4 alone or with CC for 2 hours were
monitored for the release of apoptogenic factors. Post treatment,
mitochondrial samples were resuspended and centrifuged; resul-
tant post mitochondrial supernatants and mitochondrial pellets
were monitored by western blot analyses for the release and
retention of apoptogenic factors respectively. By analyzing the
resultant mitochondrial pellet samples of U-2 OS cells, isolated U-
2 OS cell mitochondria treated with JCTH-4 retained less of the
Figure 5. JCTH-4 and CC do not yield apoptotic morphology in HOb and NFF cells. Nuclear and cellular morphology of (A) HOb and (B)
NFF cells after 72 hours of treatment. Cells were treated with JCTH-4, CC, and solvent control (Me2SO). Post treatment, the cells were stained with
Hoechst 33342 dye. Corresponding phase micrographs are shown below the Hoechst micrographs. Apoptotic morphology is evident in cells with
bright and condensed nuclei accompanied by apoptotic bodies, as well as cell shrinkage and blebbing. Images were taken at 4006magnification on
a fluorescent microscope. Scale bar=15 mm. All images are representative of 3 independent experiments.
doi:10.1371/journal.pone.0028780.g005
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release of the apoptogenic factor EndoG in a dose dependent
manner from these U-2 OS mitochondria, deduced by the analysis
of the post mitochondrial supernatants (Figure 10C). Similarly,
JCTH-4 and 5 mM CC alone caused the release of AIF from
isolated mitochondria of Saos-2 cells; however, combinatorial
treatment yielded the greatest release of AIF (Figure 10D).
The execution of apoptosis by released apoptogenic factors from
the mitochondria can be achieved with the activation of proteins
known as caspases, a family of cysteine proteases, or directly by the
apoptogenic factor [23,35]. To determine the dependence of
caspases in JCTH-4-induced apoptosis, the broad spectrum
caspase inhibitor Z-VAD-FMK was used at various doses in
combination with JCTH-4. However, as determined through the
WST-1 based colorimetric assay for cell viability, this inhibitor was
not able to protect Saos-2 cells from JCTH-4 insult (Figure 10E).
Thus, JCTH-4 exerts its cytotoxicity against OS cells in a manner
independent of caspase activation.
JCTH-4 selectively induces autophagy alone and with CC
in OS cells
Various studies have reported chemotherapeutics to trigger
both pro-death and pro-survival autophagy [36]. Moreover,
because JCTH-4 produced oxidative stress, a known autophagy
inducer, we monitored OS cells for autophagic induction following
treatment with JCTH-4 and CC. As illustrated MDC staining, OS
cells treated with various doses of JCTH-4 produced blue punctate
staining, indicative of autophagic vacuoles (Figure 11A,B). Such
staining was also seen with the combinatorial treatment of
0.25 mM JCTH-4 and 5 mM CC, but not with 5 mMC C
treatment alone (Figure 11A,B). Corresponding phase and PI
images show cell shrinkage and blebbing with JCTH-4 treatment
alone and in combination, but not with CC alone, while only
combination treatment gave some positive PI staining
(Figure 11A,B).
During autophagy, LC3 situated in the cytosol, referred to as
LC3-I, is converted to LC3-II, a lipidated form of LC3 that is
recruited to autophagosomal membranes [37]. To confirm the
induction of autophagy in OS cells, western blot analyses were
carried out on cell lysates of Saos-2 cells treated with the indicated
concentrations of JCTH-4 and CC for 72 hours to monitor the
conversion of LC3-I to LC3-II. TAM, a known inducer of
autophagy, was used as a positive control. This conversion was
enhanced with JCTH-4 at various concentrations (Figure 11C).
With the treatment of 5 mM CC alone, LC3-II conversion
decreased, and when used with 0.25 mM JCTH-4, the effect was
not significantly different from 0.25 mM JCTH-4 alone
(Figure 11C). In HOb and NFF cells, autophagic induction was
only seen in the TAM positive control groups but not in cells
treated with JCTH-4 and CC alone and in combination
(Figure 12A,B). Therefore, JCTH-4 selectively induces autophagy
in OS cells.
Discussion
In this study, we demonstrate JCTH-4 to be a highly potent
agent against OS cells. More specifically, JCTH-4 exerts its
cytotoxicity against OS by way of apoptotic induction; OS cells
treated with JCTH-4 exhibited cell shrinkage, blebbing, nuclear
Figure 6. JCTH-4 alone and in combination with CC induces phosphatidylserine externalization in OS cells. Annexin V binding to
externalized phosphatidylserine was monitored to confirm induction of apoptosis in (A) Saos-2 cells after 96 hours of treatment and (B) U-2 OS cells
after 72 hours of treatment with the indicated concentrations of JCTH-4, CC, and solvent control (Me2SO). Cells were also stained with Hoechst dye.
Images were taken at 4006 magnification on a fluorescent microscope. Green fluorescence is indicative of Annexin V binding to externalized
phosphatidylserine of the plasma membrane. Scale bar=15 mm. All images are representative of 3 independent experiments.
doi:10.1371/journal.pone.0028780.g006
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28780Figure 7. JCTH-4 alone and with CC does not induce phosphatidylserine externalization in HOb and NFF cells. Annexin V binding to
externalized phosphatidylserine was monitored to confirm that apoptosis was not induced in (A) HOb and (B) NFF cells after 72 hours of treatment.
Cells were treated with the indicated concentrations of JCTH-4, CC and solvent control (Me2SO). Cells were also stained with Hoechst dye. Images
were taken at 4006 magnification on a fluorescent microscope. Green fluorescence is indicative of Annexin V binding to externalized
phosphatidylserine of the plasma membrane. Scale bar=15 mm. All images are representative of 3 independent experiments.
doi:10.1371/journal.pone.0028780.g007
Figure 8. JCTH-4 dissipates MMP alone and in combination with CC in OS cells. Effect of JCTH-4 and CC on MMP in (A) Saos-2 cells after
96 hours of treatment and (B) U-2 OS cells after 72 hours of treatment was examined by TMRM staining. Cells were grown on coverslips, treated with
the indicated concentrations of JCTH-4, CC, and solvent control (Me2SO) and stained with TMRM and Hoechst dye. Images were taken at 4006
magnification on a fluorescent microscope. Red fluorescent punctuate marks are indicative of mitochondria with intact MMP. Scale bar=15 mm. All
images are representative of 3 independent experiments.
doi:10.1371/journal.pone.0028780.g008
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externalization, and MMP dissipation (Figure 4,6,8). Moreover,
by the end of 7 days of treatment, no viable cells were present,
indicating the absence of any resistance to this compound by OS
cells (data not shown). OS cells treated with JCTH-4 alone were
negative for PI staining, a plasma membrane impermeable DNA
stain, suggesting these cells were not dying by necrosis, a form of
cell death characterized by lysis of the plasma membrane
(Figure 11A,B) [38]. However, some PI positive staining was
present in the combination treatment with CC, which could be a
result of the permeabilization of cell membranes of late apoptotic
cells (Figure 11A,B) [39]. Considerable toxicity to non-malignant
tissue has been associated with a majority of the chemotherapeu-
tics used for OS [40–44]. However, HOb cells, a normal non-
cancerous equivalent to the OS cells used in this study, as wells as
NFF cells exhibited markedly decreased sensitivity and did not
show evident signs of apoptotic induction with JCTH-4 treatment
(Figure 2C,5,7,9); therefore, JCTH-4 is selective towards OS cells
and may prove to be a safer alternative for OS treatment to the
current chemotherapeutics in use. Such selectivity suggests a
specific target in cancer cells.
Previously, we have provided supporting evidence suggesting
that PST targets cancer cell mitochondria [13,17,18]. Compli-
menting this data, we report similar results with JCTH-4. In
addition to the JCTH-4-induced collapse of MMP in OS cells,
observations made after direct JCTH-4-insult to isolated OS
mitochondria strongly suggest this specific apoptotic activity to be
attributed to mitochondrial targeting; with regards to isolated
mitochondria from OS cells, JCTH-4 caused an increase in ROS
generation and the release of apoptogenic factors (Figure 10).
Likewise, PST selectively dissipated MMP with whole cell
treatment and caused ROS production in isolated cancer cell
mitochondria and not in non-cancerous cell mitochondria [13,14].
The well known tumor suppressor p53 causes the expression of
proapoptotic proteins that permeabilize the mitochondria in
response to different forms of intracellular stress [45]. Our results
proved JCTH-4-induced apoptosis to be p53 independent; Saos-2
cells, which do not express p53, and U-2 OS cells, with wild type
p53, were equally sensitive to JCTH-4 insult (Figure 2A,B,4)
[46,47]. This circumvention in p53 activity strengthens the
argument for a mitochondrial target as all p53 cellular events
upstream of mitochondrial permeabilization have been proven to
be insignificant in JCTH-4-induced cytotoxicity. As well as taking
part in apoptosis pathways involved with the mitochondria,
caspases are also utilized in apoptosis pathways independent of
the mitochondria [35]. Akin to PST, we have found caspases to be
nonessential in JCTH-4-induced apoptosis (Figure 10E), and that
AIF and EndoG, two apoptogenic factors involved in caspase-
independent pathways of apoptosis, are released from the
mitochondria by direct JCTH-4 insult (Figure 10C,D); thus,
caspase signalling upstream of mitochondrial membrane permea-
bilization and independent of mitochondria are not vital for the
induction of apoptosis by JCTH-4, thereby further supporting the
notion of a mitochondrial target by JCTH-4 [17,23,35,48,49]. It is
this targeting of the mitochondria that may provide the means to
cancer selectivity by JCTH-4.
Cancer cells possess many distinct characteristics, such as
marked differences in their mitochondria and energy metabolism,
which may be exploited for cancer selective therapy [50,51].
Cancer cells possess a distinct metabolic phenotype, a phenom-
Figure 9. JCTH-4 and CC do not dissipate MMP in HOb and NFF cells. Effect of JCTH-4 and CC on MMP in (A) HOb and (B) NFF cells after
72 hours of treatment was examined by TMRM staining. Cells were grown on coverslips, treated with the indicated concentrations of JCTH-4, CC, and
solvent control (Me2SO), and stained with TMRM and Hoechst dye. Images were taken at 4006 magnification on a fluorescent microscope. Red
fluorescent punctuate marks are indicative of mitochondria with intact MMP. Scale bar=15 mm. All images are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0028780.g009
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glycolysis are elevated; thus, these cells have high glucose uptake
and through the production of lactate, produce an acidic
microenvironment [52–54]. Consequently, this glycolytic shift
confers a proliferative advantage and an acquired resistance to
apoptosis in cancer cells; intermediates of glycolysis provide a vast
source of resources needed for nucleotide and lipid synthesis and
alterations of the outer mitochondrial membrane have rendered it
less susceptible to permeabilization [55–57]. Therefore, a
promising strategy in cancer therapy would be to divert cancer
cell metabolism away from glycolysis, which was demonstrated by
other efforts via the promotion of oxidative phosphorylation [58].
Such a strategy may be employed by JCTH-4. A major factor
promoting the resistance to apoptosis as a result of this metabolic
shift is the glycolytic enzyme hexokinase; its association to the
outer mitochondrial membrane has been shown to discourage
mitochondrial membrane permeabilization [59,60]. Cancer cells
have also been reported to highly express antiapoptotic members
of the Bcl-2 family of proteins and peripheral-type benzodiazepine,
all of which inhibit mitochondrial outer membrane permeabiliza-
tion [61,62]. Thus, JCTH-4 may act by targeting these proteins.
Traditional medicines have long used natural products in
treating various disorders. Modern science is now rediscovering
many of these products and their potential in rectifying numerous
Figure 10. JCTH-4 directly causes mitochondrial ROS production and release of apoptogenic factors independent of caspases. (A)
Saos-2 and (B) U-2 OS isolated mitochondria were treated directly with JCTH-4, CC, PQ, and solvent control (Me2SO), and incubated with Amplex Red
and horseradish peroxidase for 2 hours. Subsequently, fluorescence readings were taken at Ex. 560 nm and Em. 590 nm and expressed as relative
fluorescence units (RFU). Statistics were performed using GraphPad Prism version 5.0. Image is representative of 3 independent experiments
demonstrating similar trends. Values are expressed as mean 6 SD of quadruplicates of 1 independent experiment. *p,0.05, **p,0.01, ***p,0.001
versus solvent control (Me2SO); {p,0.01 versus 0.25 mM JCTH-4; @p,0.01 versus 0.5 mM JCTH-4; #p,0.01 versus 5 mM CC. Isolated mitochondria
samples treated directly with JCTH-4, CC, and solvent control (Me2SO) for 2 hours were also centrifuged, producing mitochondrial pellets and post
mitochondrial supernatants which were examined for retention and release of apoptogenic factors respectively via western blot analyses; (C)
Retention of AIF and release of EndoG by U-2 OS cell mitochondria and (D) release of AIF by Saos-2 cell mitochondria was monitored. Mitochondrial
pellets were probed for SDHA to serve as loading controls. Densitometric analyses were performed using ImageJ software and statistics were
calculated using GraphPad Prism version 5.0. Image is representative of 3 independent experiments demonstrating similar trends. Values are
expressed as mean 6 SD of triplicates of one independent experiment. *p,0.01, **p,0.001 versus solvent control (Me2SO); {p,0.01 versus 0.25 mM
JCTH-4; #p,0.01 versus 5 mM CC. (E) Saos-2 cells were treated with broad spectrum caspase inhibitor Z-VAD-FMK with and without JCTH-4 for
72 hours. WST-1 reagent was used to quantify cell viability. Absorbance was read at 450 nm and expressed as a percent of solvent control (Me2SO).
Values are expressed as mean 6 SD from quadruplicates of 3 independent experiments. *p,0.001 versus solvent control (Me2SO); ns=not
significant.
doi:10.1371/journal.pone.0028780.g010
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used to treat an array of ailments, has been recognized to possess
potent activity against numerous cancers, including OS [4,65]. As
determined by the WST-1 colorimetric assay, other reports have
established IC50 values of 17.2 mM and 21.6 mM in Saos-2 and U-
2 OS cells respectively after 72 hours [4]. By similar means, we
found 5 mM CC to have very little to no effect on these cell lines
(Figure 3A,B). However, when used with JCTH-4, CC was found
to potentiate the cytotoxic effects of JCTH-4 in both Saos-2 and
U-2 OS cells with HOb and NFF cells being markedly less
sensitive to this combinatorial treatment (Figure 3A–D). Like
JCTH-4 treatment alone, this combinatorial treatment exerts its
cytotoxicity against OS cells selectively through induction of
apoptosis (Figure 4–7). Although whole cell treatment of OS cells
with 5 mM CC did not appear to effect viability of mitochondria
(Figure 8), direct insult to isolated OS mitochondria induced ROS
production and release of AIF (Figure 10A,B,D); such discrepan-
cies between whole cell and direct mitochondrial treatment may
be attributed to low solubility or uptake of CC [66]. In accordance
with our findings, although at higher doses, other studies report
whole cell treatment with CC to induce ROS production and AIF
release from mitochondria [67,68]. Interestingly, direct treatment
of CC on OS mitochondria enhanced ROS production and AIF
release (Figure 10A,B,D). CC is known to bind and target
numerous proteins; however, these findings suggest CC to bind
either one of these known targets and/or an unknown protein,
both associated to the mitochondria [65,69]. As JCTH-4 is shown
to elicit its cancer selective effects via mitochondrial targeting, such
targeting by CC may be responsible for sensitizing OS cells to
JCTH-4-induced apoptosis.
Dual roles, both pro-death and pro-survival, have been
implicated in autophagic induction elicited by chemotherapeutic
insult [36]. JCTH-4 was found to induce autophagy at doses
between 0.25 mM and 1 mM while 5 mM CC yielded no
observable autophagic response in OS cells (Figure 11). The
autophagic response produced by the combination treatment of
5 mM CC and 0.25 mM JCTH-4 was not significantly different
from response made by the 0.25 mM JCTH-4 treatment alone; this
may indicate the enhancement in activity of JCTH-4 by CC to be
a result of targeting the apoptosis pathway rather than that of
autophagy by CC. Previous work has shown CC alone to induce
autophagy, although at much higher doses used in this study;
Figure 11. JCTH-4 induces autophagy in OS cells alone and with CC. The presence of autophagic vacuoles in (A) Saos-2 after 96 hours of
treatment and (B) U-2 OS cells after 72 hours of treatment with JCTH-4, CC, and solvent control (Me2SO) was determined by MDC staining. Bright
blue punctate marks are indicative of autophagic vacuoles. Corresponding phase and PI micrographs are shown below the MDC images. Scale
bar=15 mm. All images are representative of 3 independent experiments. (C) Cell lysates of Saos-2 cells treated with JCTH-4, CC, TAM as positive
control, and solvent control (Me2SO) for 72 hours were examined for the conversion of LC3-I to LC3-II by western blot analyses. b-actin was probed to
serve as a loading control. Densitometric analyses were done using ImageJ software and statistics were calculated using GraphPad Prism version 5.0.
Image is representative of 3 independent experiments demonstrating similar trends. Values are expressed as mean 6 SD of triplicates of one
independent experiment. *p,0.05, **p,0.01 versus solvent control (Me2SO); #p,0.01 versus 5 mM CC.
doi:10.1371/journal.pone.0028780.g011
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may be attributed to the low solubility and uptake of CC [66,70].
JCTH-4 treatment yielded autophagic induction which was
accompanied by significant cytotoxicity and cell death, as depicted
in the corresponding phase images and previous figures
(Figure 2A,B, 3A,B, 4, 6, 11A,B); this may indicate JCTH-induced
autophagy to be a detrimental response in OS cells. Such
induction was not evident in HOb and NFF cells (Figure 12A,B);
therefore, autophagic induction by JCTH-4 is selective towards
OS cells. As established in this report, JCTH-4 causes mitochon-
drial ROS production and mitochondrial dysfunction. Oxidative
stress is a known inducer of autophagy and thus, JCTH-4 may
trigger autophagy as a default mechanism [25]. Regardless,
because JCTH-4 permeabilizes OS cell mitochondria, these cells
ultimately die from apoptosis.
Recapitulating the findings of this report, JCTH-4, was found
to effectively induce apoptosis and autophagy in OS cells with
evidence suggesting this to be a result of mitochondria targeting.
Additionally, the natural compound CC was able to potentiate
these cytotoxic effects induced by JCTH-4 against OS cells.
Importantly, JCTH-4 treatment alone and in combination
proved to be selective towards OS cells as non-cancerous cells
were markedly less sensitive and did show evident signs of
apoptotic and autophagic induction. Thus, we present a
promising novel strategy, combining the novel synthetic com-
pound JCTH-4 and the natural compound CC for the treatment
of OS.
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